Human Cellular Immune Programming Against Invasive Salmonella

针对侵袭性沙门氏菌的人类细胞免疫编程

基本信息

  • 批准号:
    10454125
  • 负责人:
  • 金额:
    $ 19.02万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-08-05 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

Project Summary Invasive Salmonella disease, defined by the spread of Salmonella infection to sites distant from the gastrointestinal mucosa, is responsible for over 800,000 deaths yearly. Antimicrobial resistance is increasing against Salmonella infection, and there are no vaccines against invasive non-typhoidal Salmonella (iNTS). The proposed studies will evaluate how antigenic and phenotypic differences between different types of Salmonella, specifically S. Typhi, the two predominant iNTS strains, and typical gastroenteritis producing non-typhoidal Salmonella (NTS), impact human antigen presenting cell and T cell immune defense. The central hypothesis of this K08 application is that differences between S. Typhi, iNTS, and typical NTS lead to the initiation of different human cellular immune activation programs, which may potentially explain differences in clinical syndrome. In Aim 1 the applicant will investigate how differences between invasive and noninvasive Salmonella influence the regulation of two central cytokine pathways by human antigen presenting cells. In Aim 2, the applicant will study properties of T cells elicited in human volunteers who were previously challenged with S. Typhi, for potential cross-reactive T cell memory functions against iNTS. Aim 3 will involve analysis of differences in human macrophage activation programs between the two predominant iNTS strains and typical NTS. Understanding pathways of immune recognition, immune activation, and properties of T cell memory against invasive Salmonella may help to guide rational vaccine design against this neglected infection. This K08 application details a comprehensive, integrated 5-year training period with the goal of building from the applicant’s existing background in immunology and infectious diseases while developing new scientific skills and leadership in human cellular immunology. The applicant’s central goal for K08 training is to launch a career as an independent physician-scientist and leader in the immunology of neglected enteric infectious diseases and vaccinology. The proposal summarizes a plan for robust mentorship and scientific training, as well as foundational educational, professional, and career development activities. The K08 project will be conducted at the University of Maryland Center for Vaccine Development, an exceptional environment for research and training in translational human immunology against Salmonella, and vaccinology.
项目摘要 侵袭性沙门氏菌病,定义为沙门氏菌感染传播到远离 胃肠道粘膜,每年造成超过800,000人死亡。抗生素耐药性正在增加 目前还没有针对侵袭性非伤寒沙门氏菌(iNTS)的疫苗。的 拟议的研究将评估不同类型沙门氏菌之间的抗原性和表型差异, 特别是S。伤寒,两种主要的iNTS菌株,以及典型的非伤寒性胃肠炎 沙门氏菌(NTS),影响人类抗原呈递细胞和T细胞免疫防御。核心假设 该K08申请的一个优点是S.伤寒、iNTS和典型的NTS导致不同的 人类细胞免疫激活程序,这可能潜在地解释临床综合征的差异。在 目的1申请人将研究侵袭性和非侵袭性沙门氏菌之间的差异如何影响 人抗原呈递细胞对两种中心细胞因子途径的调节。在目标2中,申请人将学习 在先前用S.伤寒,潜在的 交叉反应性T细胞记忆功能对抗iNTS。目标3将涉及分析人类 两种主要iNTS菌株和典型NTS之间的巨噬细胞活化程序。理解 免疫识别途径、免疫激活和T细胞记忆对抗侵袭性 沙门氏菌可能有助于指导针对这种被忽视的感染的合理疫苗设计。 此K08应用程序详细介绍了一个全面的,综合的5年培训期,目标是建立 从申请人现有的免疫学和传染病背景,同时开发新的科学 在人类细胞免疫学方面的技能和领导力。申请人K08培训的中心目标是启动一个 职业生涯作为一个独立的医生,科学家和领导者在免疫学被忽视的肠道传染病 疾病和疫苗学。该提案还概述了一项强有力的指导和科学培训计划 作为基础教育,专业和职业发展活动。K08项目将在 在马里兰州大学疫苗开发中心, 在翻译人类免疫学对沙门氏菌和疫苗学的培训。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

REKHA R RAPAKA其他文献

REKHA R RAPAKA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('REKHA R RAPAKA', 18)}}的其他基金

Human Cellular Immune Programming Against Invasive Salmonella
针对侵袭性沙门氏菌的人类细胞免疫编程
  • 批准号:
    10216989
  • 财政年份:
    2019
  • 资助金额:
    $ 19.02万
  • 项目类别:
Human Cellular Immune Programming Against Invasive Salmonella
针对侵袭性沙门氏菌的人类细胞免疫编程
  • 批准号:
    10755394
  • 财政年份:
    2019
  • 资助金额:
    $ 19.02万
  • 项目类别:
Determinants of antibody-based host resistance against Pneumocystis carinii
基于抗体的宿主对卡氏肺孢子虫耐药性的决定因素
  • 批准号:
    7221524
  • 财政年份:
    2006
  • 资助金额:
    $ 19.02万
  • 项目类别:
Determinants of antibody-based host resistance against Pneumocystis carinii
基于抗体的宿主对卡氏肺孢子虫耐药性的决定因素
  • 批准号:
    7758657
  • 财政年份:
    2006
  • 资助金额:
    $ 19.02万
  • 项目类别:
Determinants of antibody-based host resistance against Pneumocystis carinii
基于抗体的宿主对卡氏肺孢子虫耐药性的决定因素
  • 批准号:
    7682231
  • 财政年份:
    2006
  • 资助金额:
    $ 19.02万
  • 项目类别:
Determinants of antibody-based host resistance against Pneumocystis carinii
基于抗体的宿主对卡氏肺孢子虫耐药性的决定因素
  • 批准号:
    7285599
  • 财政年份:
    2006
  • 资助金额:
    $ 19.02万
  • 项目类别:

相似海外基金

Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
  • 批准号:
    10836880
  • 财政年份:
    2023
  • 资助金额:
    $ 19.02万
  • 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
  • 批准号:
    10734324
  • 财政年份:
    2023
  • 资助金额:
    $ 19.02万
  • 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 19.02万
  • 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
  • 批准号:
    23K04971
  • 财政年份:
    2023
  • 资助金额:
    $ 19.02万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
  • 批准号:
    2885451
  • 财政年份:
    2023
  • 资助金额:
    $ 19.02万
  • 项目类别:
    Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
  • 批准号:
    10385926
  • 财政年份:
    2022
  • 资助金额:
    $ 19.02万
  • 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
  • 批准号:
    10509043
  • 财政年份:
    2022
  • 资助金额:
    $ 19.02万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10704008
  • 财政年份:
    2022
  • 资助金额:
    $ 19.02万
  • 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
  • 批准号:
    10818273
  • 财政年份:
    2022
  • 资助金额:
    $ 19.02万
  • 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
  • 批准号:
    10349397
  • 财政年份:
    2022
  • 资助金额:
    $ 19.02万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了